Zacks Research Issues Negative Estimate for HALO Earnings

Key Points

• Zacks Research has lowered its Q3 2025 earnings estimate for Halozyme Therapeutics to $1.50 per share, down from $1.51, while maintaining a "Hold" rating.
• Analysts have mixed ratings on the stock, with six giving it a Buy rating, five a Hold, and two a Sell, while the average price target stands at $70.44.
• The company reported earnings of $1.54 per share in its last quarter, exceeding expectations and showing a revenue increase of 40.8% year-over-year.

Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) - Equities research analysts at Zacks Research lowered their Q3 2025 earnings estimates for Halozyme Therapeutics in a report issued on Tuesday, October 7th. Zacks Research analyst Team now expects that the biopharmaceutical company will post earnings per share of $1.50 for the quarter, down from their previous estimate of $1.51. Zacks Research currently has a "Hold" rating on the stock. The consensus estimate for Halozyme Therapeutics' current full-year earnings is $4.73 per share. Zacks Research also issued estimates for Halozyme Therapeutics' Q1 2027 earnings at $1.32 EPS, Q3 2027 earnings at $1.65 EPS and FY2027 earnings at $6.90 EPS.

HALO has been the subject of a number of other research reports. Weiss Ratings raised shares of Halozyme Therapeutics from a "hold (c+)" rating to a "buy (b-)" rating in a report on Wednesday. JPMorgan Chase & Co. raised their price target on shares of Halozyme Therapeutics from $60.00 to $63.00 and gave the company a "neutral" rating in a report on Thursday, August 7th. The Goldman Sachs Group began coverage on shares of Halozyme Therapeutics in a report on Thursday, July 10th. They issued a "neutral" rating and a $55.00 price target for the company. HC Wainwright raised their price target on shares of Halozyme Therapeutics from $85.00 to $90.00 and gave the company a "buy" rating in a report on Thursday, October 2nd. Finally, Wall Street Zen cut shares of Halozyme Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Friday, September 5th. Six research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, Halozyme Therapeutics has a consensus rating of "Hold" and an average price target of $70.44.

Halozyme Therapeutics Stock Performance

NASDAQ HALO opened at $65.20 on Thursday. The firm has a market cap of $7.63 billion, a price-to-earnings ratio of 14.92, a PEG ratio of 0.35 and a beta of 1.16. The company has a 50 day moving average of $70.87 and a 200-day moving average of $62.00. The company has a current ratio of 8.36, a quick ratio of 7.01 and a debt-to-equity ratio of 4.54. Halozyme Therapeutics has a 1-year low of $42.01 and a 1-year high of $79.50.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share for the quarter, topping the consensus estimate of $1.23 by $0.31. The company had revenue of $325.72 million during the quarter, compared to analyst estimates of $282.66 million. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. The company's revenue was up 40.8% on a year-over-year basis. During the same quarter last year, the business posted $0.91 earnings per share. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS.

Institutional Investors Weigh In On Halozyme Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. GAMMA Investing LLC lifted its position in Halozyme Therapeutics by 33.5% during the 3rd quarter. GAMMA Investing LLC now owns 3,758 shares of the biopharmaceutical company's stock worth $276,000 after buying an additional 943 shares in the last quarter. Osaic Holdings Inc. lifted its position in Halozyme Therapeutics by 80.9% during the 2nd quarter. Osaic Holdings Inc. now owns 53,448 shares of the biopharmaceutical company's stock worth $2,972,000 after buying an additional 23,910 shares in the last quarter. Cim Investment Management Inc. lifted its position in Halozyme Therapeutics by 100.7% during the 2nd quarter. Cim Investment Management Inc. now owns 17,924 shares of the biopharmaceutical company's stock worth $894,000 after buying an additional 8,995 shares in the last quarter. Newbridge Financial Services Group Inc. bought a new stake in Halozyme Therapeutics during the 2nd quarter worth about $32,000. Finally, Advisory Services Network LLC bought a new stake in Halozyme Therapeutics during the 2nd quarter worth about $606,000. 97.79% of the stock is owned by institutional investors.

Insider Activity

In related news, CEO Helen Torley sold 20,000 shares of the business's stock in a transaction on Wednesday, October 1st. The shares were sold at an average price of $75.35, for a total value of $1,507,000.00. Following the sale, the chief executive officer directly owned 733,719 shares of the company's stock, valued at approximately $55,285,726.65. The trade was a 2.65% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Nicole Labrosse sold 20,000 shares of the business's stock in a transaction on Wednesday, September 10th. The shares were sold at an average price of $75.71, for a total transaction of $1,514,200.00. Following the completion of the sale, the chief financial officer directly owned 24,306 shares in the company, valued at $1,840,207.26. This represents a 45.14% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 108,227 shares of company stock valued at $7,779,595 in the last quarter. Company insiders own 2.40% of the company's stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.